Cogent Biosciences Inc. (COGT) Set for Bezuclastinib Launch, Awaiting FDA Approval
Cogent Biosciences Inc. (NASDAQ:COGT) is one of the best cancer stocks to invest in now. On February 17, CEO Andrew Robbins reiterated that Cogent Biosciences Inc. (NASDAQ:COGT) has started 2026 with tremendous momentum backed by multiple value-creating regulatory catalysts.
In January, the US Food and Drug Administration accepted the company’s PEAK New Drug Application for bezuclastinib in patients with Gastrointestinal Stromal Tumors (GIST). Consequently, the company submitted to the FDA, having already secured Breakthrough Therapy Designation.
The slate of positive regulatory milestones comes on the candidate drug showing clear clinical benefit across all symptom domains. Cogent Biosciences is on the cusp of launching bezuclastinib in the second half of 2026, awaiting FDA approval.
Six Abstracts from the SUMMIT trial of bezuclastinib in patients with Non-Advanced Systemic Mastocytosis (NonAdvSM) have already been accepted for presentation at the 2026 AAAAI annual meeting.
Cogent Biosciences exited 2025 with $900.8 million in cash equivalents and marketable securities, having repaid $54.8 million of long-term debt in the fourth quarter. Research and development expenses increased to $75.6 million in the fourth quarter of 2025 from $62 million in the fourth quarter of 2024.
On the other hand, full-year R&D totaled $269.8 million, up from $232.7 million in 2024. Net loss widened to $102.5 million in the fourth quarter and to $328.9 million for the full year 2025, compared to $67.9 million and $255.9 million for the fourth quarter and full year 2024, respectively .
Cogent Biosciences Inc. (NASDAQ:COGT) is a clinical-stage biotechnology company focused on developing precision therapies for genetically defined diseases. Their primary drug candidate, bezuclastinib (CGT9486), is a potent, selective inhibitor designed to treat systemic mastocytosis and advanced gastrointestinal stromal tumors (GIST) by targeting the KIT D816V mutation.
While we acknowledge the potential of COGT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
XRP Pundit: First Thing You Should Do When You Become a Crypto Millionaire
VIPTradFi Focus: Where Does the RWA Market Stand Today?
1. Crypto outperformed traditional equity indexes following the rate hike, but elevated interest rates remain a key constraint on cross-asset allocation. From September 12 to 18, BTC, ETH, and SOL gained 4.83%, 3.84%, and 9.96%, respectively, while the S&P 500 edged down 0.08%. The U.S. Dollar Index rose 1.11%, and the 10-year U.S. Treasury yield closed at approximately 4.998%. Improving risk appetite is therefore coexisting with elevated discount rates, raising the bar for RWA allocation: investors need to compare not only returns on the underlying assets, but also on-chain liquidity and collateral efficiency. 2. Growth in tokenized equities is occurring even as the overall RWA market remains under pressure. As of September 18, Distributed Asset Value across RWAs stood at $38.503 billion, down 1.13% week over week, while tokenized equities reached $3.056 billion, up 6.03%. This week's data are better explained by capital reallocating across different RWA segments than by a broad-based expansion of the entire RWA market. 3. For exchanges, the opportunity lies in connecting spot holdings, collateral, and derivatives. Reality's distributed asset value stands at approximately $155 million, while eligible rTokens can already be used within Bitget's UTA margin framework. Across CoinGlass's verifiable sample of 177 TradFi instruments, open interest reached approximately $11.498 billion, up 2.06% week over week, even as weekly trading volume declined 7.60%. The medium-term opportunity remains intact, but deeper utilization will depend on liquidity, collateral use, and sustained trading activity. 4.Assets to watch: BTC, ETH, SOL, NEAR, ZEC, gold, tokenized U.S. equities, COST. 5.Key metrics to watch: rToken collateral utilization, the durability of TradFi open interest and trading volume, and next week's employment and consumer data.
Gold prices fall Rs 1,331/10 gram, silver dips Rs 1,600/kg as Mideast tensions outweigh oil fall: Key levels to track
Strategists Say Market's ‘Wall of Worry' Is Healthy, Not a Warning Sign
Crypto prices
More
